Category: Sectors

Categories
Dividend Stocks

Magellan Financial Group Ltd Loses Largest Mandate; FVE reduced to AUD 38

Business Strategy and Outlook

Magellan is an active manager of listed equities and infrastructure. The firm has had considerable success in growing funds under management, or FUM, owing to its superior track record of outperformance, product expansion initiatives, and strong distribution capabilities.

The firm has a fundamental, high-conviction investment approach. Its flagship Global strategy has historically tilted toward IT, e-commerce platforms, and consumer franchises; preferring large, developed market multinationals. FUM have been attracted by consistently achieving excess returns with lower volatility and drawdowns relative to peers.Magellan’s products are well-distributed. Its funds are featured across platforms, included in model portfolios, and are well-rated. 

There is a focus on targeting retail investors, with product expansion an increasingly common driver of growth. As per Morningstar analyst, Magellan has built the foundations for ongoing earnings growth, supported by its economic moat, product variety, and historically strong track record. Regardless, the potential earnings upside from these positive traits will take time to manifest.

Magellan Loses Largest Mandate, but Sell-Off Way Overdone

Morningstar analyst reduced its fair value estimate for Magellan Financial Group by 25% to AUD 38 per share, following client the termination of its mandate with its largest client, St James’s Place, or SJP. As per the viewpoint of Morningstar analyst, most of Magellan’s institutional clients hired the group to deliver returns of about 10% per year and focus on downside protection. It is an investment undertaking Magellan has always communicated to the market, and a hurdle it consistently surpassed, with institutional returns averaging 18% per year over the last five years. As Magellan’s recent underperformance has only begun since November 2020, it was believed that institutional clients would negotiate for lower fees rather than terminate Magellan. Regretfully, this has not transpired in SJP’s case.

Financial Strength

Magellan is in sound financial health.The firm has a conservative balance sheet with no debt, with its financial position also boosted by solid operating cash flows. As of June 30, 2021, Magellan had cash and equivalents of about AUD 212 million and financial investments with a net fair value of around AUD 453 million mainly invested in its own unlisted funds and listed shares. This should provide it with enough liquidity to cope with most market conditions. Its high dividend payout ratio of: (1) 90%-95% of the net profit after tax of its core funds management business before performance fees; and (2) annual performance fee dividend in the range of 90%-95% of net crystallised performance fees aftertax reflects the capital-light nature of asset management.

Bull Says

  • The majority of Magellan’s earnings come from a few large funds, meaning it has a high reliance on key investment personnel and the performance of its main funds. Should key people leave, or its main funds underperform for a sustained period, outflows could be material. 
  • There is increasing competition from other active international equity managers and new international equity funds from incumbents. 
  • The firm faces fee pressure from the increasing popularity of lower-cost alternatives, such as indextype products and ETFs.

Company Profile

Magellan Financial Group is an Australia-based niche funds manager. Established in 2006, the firm specialises in the management of equity and infrastructure funds for domestic retail and institutional investors. Magellan has been particularly successful in winning mandates from global institutional investors. Current FUM is split across global equities, infrastructure and Australian equities

(Source: Morning Star)

General Advice Warning

Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.

Categories
Technology Stocks

Omicron Buoys Sonic Healthcare Coronavirus Testing but Our Long-Term View Stands

Business Strategy and Outlook

Sonic’s “medical leadership” model recognises the importance of the referring doctor as the company seeks to differentiate itself on service levels. Success in the model is evidenced by organic growth consistently tracking ahead of the market, suggesting market share gains. Sonic’s organic volume growth in its core laboratories segment has typically ranged between 3% and 4% and we forecast a similar rate over our 10-year forecast period. The volume growth is underpinned by population growth, aging demographics in developed markets, higher incidence of diseases and wider adoption of preventative diagnostics to manage healthcare costs.

Laboratory medicine, or pathology, has a high fixed cost of operation and thus benefits from volume growth to drive lower cost per test outcomes. Sonic benefits from cost efficiencies by maximising throughput through its network of labs and collection centres. Higher testing volumes result in a lower cost per test as labour, equipment, leases, transportation and overhead costs are all leveraged.

Financial Strength

Sonic is in a strong financial position. Free cash flow conversion of earnings prior to acquisition spend has averaged 98% over the last 10 years and has allowed Sonic to quickly repay the debt funding its acquisitions. At the end of fiscal 2021, Sonic reported AUD 921 million in net debt representing net debt/EBITDA of only 0.4 times, below the 2.0 to 2.7 times range targeted by management, and well below the 3.5 times covenant. Sonic also has a progressive dividend policy which is communicated as a minimum of an equal dividend per share to the prior year.

Our AUD 33 fair value estimate factors in 4% group revenue growth in a typical year and a midcycle operating margin of 14%. It is estimated that the deliver EPS growth of roughly 5% in a typical year. Partly offsetting this was the Australian government cutting the reimbursement rate for private providers to AUD 72.25 per test from AUD 85 prior, which is in place until June 30, 2022. The deal broadens Sonic’s existing U.S. footprint by instantly adding annualised revenue of roughly USD 110 million, or 7% of Sonic’s fiscal 2021 U.S. laboratory revenue.

Bulls Say’s 

  • Sonic boasts leading market positions in most of its geographies and benefits from cost advantage derived from scale. 
  • Pathology and diagnostic imaging are highly defensive industries that influence the majority of treatment decisions. 
  • Free cash flow conversion prior to acquisition spend has averaged 98% of earnings over the preceding 10 years and forecast to remain high, allowing Sonic ample flexibility to reinvest in the business.

Company Profile 

Sonic Healthcare is a global pathology provider. It is the largest private operator in Australia, Germany, Switzerland and the U.K., the second largest in Belgium and New Zealand and the third largest in the U.S. In addition to pathology, which contributes roughly 85% of group revenue, Sonic is the second largest player in diagnostic imaging in Australia and the largest operator of medical centres in Australia. The company typically earns about 40% of group revenue in Australia and New Zealand, 25% in the U.S. and 35% in Europe

(Source: Morningstar)

General Advice Warning

Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.

Categories
Technology Stocks

Adobe’s ARR Slip-Up and Light Guidance for 2022 Leave Shares Attractive; FVE Up to $630

Business Strategy and Outlook

Adobe has come to dominate in content creation software with its iconic Photoshop and Illustrator solutions, both now part of the broader Creative Cloud, which is now offered via a subscription model. The company has added new products and features to the suite through organic development and bolt-on acquisitions to drive the most comprehensive portfolio of tools used in print, digital, and video content creation The benefits from software as a service are well known in that it offers significantly improved revenue visibility and the elimination of piracy for the company, and a much lower cost hurdle to overcome and a solution that is regularly updated with new features for users.

Adobe benefits from the natural cross-selling opportunity from Creative Cloud to the business and operational aspects of marketing and advertising. It is expected that Adobe will continue to focus its M&A efforts on the digital experience segment and other emerging areas. Adobe believes it is attacking an addressable market greater than $205 billion. The company is introducing and leveraging features across its various cloud offerings (like Sensei artificial intelligence) to drive a more cohesive experience, win new clients, upsell users to higher price point solutions, and cross sell digital media offerings.

Adobe’s ARR Slip-Up and Light Guidance for 2022 Leave Shares Attractive; FVE Up to $630

Adobe reported mixed fourth-quarter results, including revenue upside, messy billings, modest EPS upside, and light guidance. However, Morningstar analyst believe the outlook is better than it appears. After all, the 2022 outlook is just 1% below FactSet consensus, with pressure driven by having one less week than 2021 and foreign exchange combining to add a 300 basis point headwind to growth. After factoring guidance and results along with rolling with DCF forward,  analyst of Morningstar have raised fair value estimate to $630 per share from $610. 

Financial Strength 

Adobe enjoys a position of excellent financial strength arising from its strong balance sheet, growing revenues, and high and expanding margins. As of November 2021, Adobe has $5.8 billion in cash and equivalents, offset by $4.1 billion in debt, resulting in a net cash position of $1.6 billion. Adobe has historically generated strong operating margins. Free cash flow generation was $6.9 billion in fiscal 2021, representing a free cash flow margin of 43.7%.Morningstar analyst believes that margins should continue to grind higher over time as the digital experience segment scales. In terms of capital deployment, Adobe reinvests for growth, repurchases shares, and makes acquisitions. The company does not pay a dividend. Over the last three years Adobe has spent $2.8 billion on acquisitions, $9.6 billion on buy-backs, while share count has decreased by 15 million shares. Morningstar analyst believes that the company will continue to repurchase shares as its primary means of returning cash to shareholders over the medium term and will continue to make opportunistic and strategic tuck-in acquisitions.

Bulls Say 

  • Adobe is the de facto standard in content creation software and PDF file editing, categories the company created and still dominates. 
  • Shift to subscriptions eliminates piracy and makes revenue recurring, while removing the high up-front price for customers. Growth has accelerated and margins are expanding from the initial conversion inflection. 
  • Adobe is extending its empire in the creative world from content creation to marketing services more broadly through the expansion of its digital experience segment. This segment should drive growth in the coming years.

Company Profile

Adobe provides content creation, document management, and digital marketing and advertising software and services to creative professionals and marketers for creating, managing, delivering, measuring, optimizing and engaging with compelling content multiple operating systems, devices and media. The company operates with three segments: digital media content creation, digital experience for marketing solutions, and publishing for legacy products (less than 5% of revenue).

 (Source: Morningstar)

General Advice Warning

Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.

Categories
Technology Stocks

Visa Inc. FY21reported solid results driven by diversification of revenue and recovery of global economies

Investment Thesis 

  • Stands to benefit from the increased digitization of money with the global amount of payments made via card or digitally exceeding physical cash for the first time in 2016. 
  • Expansion of new flows and use cases. 
  • Visa stands to benefit from the improving momentum in Europe and India. 
  •  Strong partnerships with first class financial institutions including increased ease in working with fintech partners (as Visa opens up its APIs to fintechs). 
  •  Continued investment in technology and cyber security. 
  •  Strong management team. 
  • Solid fundamentals with recurring revenues, high incremental margins, low capital expenditure and high free cash flow.

Key Risks

  • Cyber security attacks. 
  • Increased regulatory environment and government-imposed restrictions on payment systems. Antitrust remains a hot topic in the market. 
  •  Margin deterioration due to intense competition from alternative payment processing providers. 
  • Higher expenses and incentives. 
  •  Deterioration in global growth or consumption.

FY21 Results Highlights

V’s FY21 results beat consensus estimates with net revenue of $24.1bn (vs $24bn), driven by the continuation of the recovery in many global economies and the increased diversification of revenue with new flows and VAS. Cashflow generation remained strong (FCF up +50% over pcp) and shareholder returns continued with the Board authorizing a +17% increase in the quarterly dividend in addition to conducting $8.7bn in repurchases (has $4.7bn of remaining authorized funds for share repurchase). Maintain Buy – solid top-line growth over the medium term amid buildout of new payment types – BNPL, cryptocurrency and B2B – with recovering credit and crossborder travel and new flows in VAS (amid strong demand for cybersecurity, marketing and data analytics) driving further acceleration. In the near-term, a faster than expected recovery in cross-border travel could represent upside to management (expected to reach 2019 levels by summer 2023) and consensus earnings estimates.

Outlook

Management expects: (1) 1Q22 net revenue growth in the high teens (will moderate through the year), client incentives as a percentage of gross revenue to be 26- 27% (in-line with 4Q21), operating expenses growth in the mid-teens amid sustained investment spending combined with low comparable in pcp, non-operating expense of $120- 130m, and tax rates of 19-19.5%. (2) FY22 value-added services growth of high teens and client incentives as a percent of gross revenues of 26-27% (consistent with 4Q21 levels, gradually reaching pre-Covid growth of +50-100bps each year due to the impact of new deals and renewals), which combined with the expected benefit from revenue mix improvement as cross-border travel continues to recover (cross-border travel is expected to recover steadily through FY22 and reach 2019 levels by the summer of 2023). Partially offset by the lapping of incentive reductions from FY21 due to the Covid impact, resulting in high end or mid-teens net revenue growth (including over 0.5% of exchange rate drag from the strengthening dollar). Operating expenses to grow in the low teens, with expense growth higher in 1H22 and moderate in 2H22 as the Company lap the resumption of investment spending in FY21, non-operating expense to be $120-130m each quarter and tax rate to be 19-19.5%. 

Company Profile

Visa Inc. (NYSE: V) is the world’s leader in digital payments and one of the most recognized brands around the world, with a mission to connect the world through innovative, reliable and secure payment networks, enabling individuals, businesses and economies to thrive. The Company’s advanced global processing network, VisaNet, facilitates authorization, clearing and settlement of payment transactions, providing secure and reliable payments across borders and within countries. The Company operates in party models, which include card issuing financial institutions, acquirers and merchants. The Company’s products/services include core products, processing infrastructure, transaction processing services, digital products, merchant products, and risk products and payment security initiatives. Its relentless focus on innovation is a catalyst for the rapid growth of connected commerce on any device, and a driving force behind the dream of a cashless future for everyone, everywhere.

General Advice Warning

Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.

Categories
Dividend Stocks

CSL Ltd. : Pioneering in Global Biotechnology

Business Strategy and Outlook

CSL is one of three tier one plasma therapy companies who benefit from an oligopoly in a highly consolidated market. All the players are vertically integrated as plasma sourcing is a key constraint in production. The plasma sourcing market is currently in short supply, however, CSL is well-positioned having invested significantly in plasma collection centres, owning roughly 30% of collection centres globally. 

One major threat to plasma products is recombinant products. Recombinants are quickly replacing plasma products in haemophilia treatment despite being more expensive. CSL has an excellent R&D track record and has developed recombinant products for haemophilia. However, we expect revenue growth to slow in the haemophilia segment based on competitor Roche’s successful launch of recombinant Hemlibra. Immunoglobulin product sales are key to CSL.

This market is not yet impacted by recombinants although both CSL and competitors are pursuing R&D in Fc receptor-targeting therapy to treat autoimmune diseases. 

However, gene therapy represents the biggest risk to the plasma industry as it aims to cure rather than treat diseases. While the potentially prohibitive cost may result in slow adoption, CSL has strategically expanded its scope via the acquisition of Calimmune in fiscal 2018 and licensing a late-stage Haemophilia B gene therapy, EtranaDez, from UniQure in fiscal 2020. 

CSL is the second largest influenza vaccine manufacturer, behind Sanofi, and is on the forefront of changes in influenza vaccines where manufacturing is shifting from egg-based to cell-based culturing. It’s also conducting preclinical testing of mRNA influenza vaccines. 

The company has demonstrated good sense for R&D and evaluates spend based on the commercial outlook. The strategy for CSL Behring has been to target rare diseases, a typically low volume and high price and margin business. There is little reimbursement risk in this area or in the vaccine business, Seqirus.

Financial Strength

CSL is in good financial health and can fund all its capital and R&D spending, currently a combined 26% of revenue, as well as maintain a dividend payout ratio of 44% without requiring additional debt. Following the acquisition of Vifor Pharma, financial leverage is expected to increase to 2.3 in fiscal 2023. However, it is forecasted that the net debt/EBITDA may fall within CSL’s target range of 1.0-1.5 by fiscal 2026. This leaves CSL flexible to pursue organic or acquisitive growth opportunities as they present in the evolving biotech industry.

Free cash flow conversion has remained depressed over the last five years as working capital investment and capital spending to add manufacturing capacity was elevated above long-term levels, combined with higher R&D spending. We forecast free cash conversion to improve but still average 52% over the next five years as we anticipate CSL to prefer growing organically rather than acquisitively.

Bulls Say’s

  • CSL is investing in both physical capacity and R&D, leaving it well-positioned to take advantage of growth opportunities in the key immunoglobulins market. 
  • The acquisition of Calimmune’s gene therapy platform in fiscal 2018 and UniQure’s late-stage haemophilia B gene therapy candidate in fiscal 2020 will help defend against emerging competition. 
  • CSL has a strong R&D track record, and the ongoing rate of investment is ahead of major competitors.

Company Profile 

CSL is one of the largest global biotech companies and has two main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders and neurological indications. Seqirus is now the world’s second largest influenza vaccination business and was acquired in fiscal 2015. CSL has a strong R&D track record, and the product portfolio and pipeline include non-plasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe

(Source: MorningStar)

General Advice Warning

Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.

Categories
Funds Funds

CFS Index Australian Bond: Simple and reasonably priced choice for diversified Australian bond exposure

Approach

FSI matches the risk factors of the benchmark, including duration, sector exposures, and credit quality by employing a full replication method. The strategy can hold securities that have been or are expected to be included in the index, and it can exclude those likely to drop in or out. On average, the cash holding would be in the vicinity of 0.5% because of the impact of daily flows and liquidity needs. The larger asset base gives the firm the benefit of scale and helps to keep a lid on overall transaction costs. FSI uses the BlackRock Aladdin portfolio management tool to manage the index-tracking process end to end, including trading and risk assessment and monitoring.

Portfolio

CFS Index Australian Bond replicates the Bloomberg AusBond Composite 0+ Year Index fully. As of 30 September 2021, the fund is composed mainly of Treasury (56.6%) and government-related (semigovernment and supranational) debt (36.4%). Corporate credit constitutes most of the remaining portion of the fund. A major portion of the credits in the index are issued by banks, followed by diversified financials and real estate trusts. . The concentrated credit exposure to banks and financials means Australian property fundamentals play a role in the portfolio’s performance in the long run.

People

FSI has a long history of managing passive strategies. FSI’s institutional passive funds under management is substantial. As of August 2021, FSI had around $5.1 billion in active funds and $12.2 billion in passive strategies. The Australian fixed-income team headed by Stephen Cooper within FSI is responsible for the CFS Index Australia Bond Fund. Cooper is an industry veteran. He is supported by four portfolio managers in the team, with Darja Milosevic and Alex Nikolovski dedicated to passive vehicles.

Performance 

As a core bond holding, CFS Index Australia Bond has served investors well over time by bringing broader portfolio volatility down and protecting capital when equity market slides. On the other hand, it has lagged when yields rose and when credit markets have been strong. This was evident in 2013 when the fund’s 1.7% gain trailed over half of its category peers or when yields rose toward the second half of 2020 through the end of the first quarter of 2021 (November 2020–March 2021). Encouragingly, the fund had done well when equity markets were weak. Its relatively long duration and high-quality exposure have been a boon during such occasions. 

CFS Performance.png

About the Fund

CFS Wholesale Indexed Australian Bond Fund is a unit trust incorporated in Australia. The objective of the Fund is to closely track the UBS Warburg Australian Composite Bond Index, All Maturities. The Fund invests in securities issued or guaranteed by governments, statutory authorities, banks, and corporations of a high credit standing, with some cash for liquidity.

(Source: Morningstar)

General Advice Warning

Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.

Categories
Global stocks Shares

Deere’s Prospects for Fiscal 2022 Look Bright to Us, Given Strong End Market Demand

Business Strategy and Outlook

Deere’s strong brand is underpinned by its high-quality, extremely durable, and efficient products. Customers in developed markets also value Deere’s ability to reduce the total cost of ownership. The company’s strategy focuses on delivering a comprehensive solution for farmers. Deere’s innovative products target each phase of the farming process, which includes field preparation, planting and seeding, applying chemicals, and harvesting. The company also embeds technology in its products, from guidance systems to seed placement and spacing and customized spraying applications. Deere is committed to expanding customer offerings and providing value-added services. Additionally, we believe the management team will look to reduce the company’s cost structure as some markets have matured, providing an opportunity to rethink its footprint and create a leaner organization.

Financial Strength 

Deere maintains a sound balance sheet. On the industrial side, the net debt/adjusted EBITDA ratio was relatively low at the end of fiscal 2021, coming in at 0.4. Total outstanding debt, including both short- and long-term debt, was $10.4 billion. Deere’s strong balance sheet gives management the financial flexibility to run a balanced capital allocation strategy going forward that mostly favors organic growth and also returns cash to shareholders. The company’s cash position as of fiscal year-end 2021 stood at $7.2 billion on its industrial balance sheet. We also find comfort in Deere’s ability to tap into available lines of credit to meet any short-term needs. Deere has access to $5.7 billion in credit facilities.

Additionally, management is determined to rationalize its footprint by reducing the number of facilities in mature markets. If successful, this will put Deere on much better footing from a cost perspective, further supporting its ability to return cash to shareholders. The captive finance arm holds considerably more debt than the industrial business, but this is reasonable, given its status as a lender to both customers and dealers. Total debt stood at $38 billion in fiscal 2021, along with $38 billion in finance receivables and $829 million in cash. In our view, Deere enjoys a strong financial position supported by a clean balance sheet and strong free cash flow prospects.

Bulls Say’s

  • Higher crop prices encourage farmers to grow more crops and will lead to more farming equipment purchases, substantially boosting Deere’s revenue growth. 
  • Deere will benefit from strong replacement demand, as uncertainty around trade, weather, and agriculture commodity demand has eased, encouraging farmers to refresh their machine fleet. 
  • Increased infrastructure spending in the U.S. and emerging markets will lead to more construction equipment purchases, benefiting Deere.

Company Profile 

Deere is the world’s leading manufacturer of agricultural equipment, producing some of the most recognizable machines in the heavy machinery industry. The company is divided into four reportable segments: production and precision agriculture, small agriculture and turf, construction and forestry, and John Deere Capital. Its products are available through a robust dealer network, which includes over 1,900 dealer locations in North America and approximately 3,700 locations globally. John Deere Capital provides retail financing for machinery to its customers, in addition to wholesale financing for dealers, which increases the likelihood of Deere product sales.

(Source: Morningstar)

General Advice Warning

Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.

Categories
Dividend Stocks Philosophy Technical Picks

AUB Group Ltd. visions to boost EPS growth with acquisition strategies

Business Strategy and Outlook

AUB operates the second-largest general insurance broker network in Australia and New Zealand. AUB brokers derive revenue from commissions paid by insurers, based on gross written premiums. AUB owns or has equity stakes in each broking business within the network. Post the exit of rehabilitation services in 2021, around 85% of group EBITA is delivered by the broker network, while the underwriting agencies generate about 15%.

A key value proposition over smaller brokers is AUB’s ability to negotiate more favourable policy wording and pricing. Scale also provides the capacity to spend more on technology, which helps facilitate greater analytical and processing capabilities, and marketing to help attract and retain customers. Other services such as claims support and premium funding support the value proposition.

AUB’s underwriting agencies distribute insurance products but take no underwriting risk. Underwriting agencies act on behalf of insurers to design, develop, and provide specialised insurance products and services.

The earnings outlook is positive. It is expected further insurance price rises over the medium term as insurers seek to cover claims inflation and weak investment income. This follows a weak pricing environment due to excess global reinsurance capacity, soft economic conditions, and elevated competition.

Financial Strength

AUB is in sound financial health. It has strong cash flow generation with a high conversion of earnings to operating cash flow and a relatively high dividend pay-out ratio. Gearing as reported by the company (corporate, subsidiary and look through share of associate debt/debt plus equity) ratio is reasonable, at 28.5% and below the firm’s maximum 45% ratio. Excluding customer cash for premium held by AUB but payable to insurers, AUB holds AUD 90 million in cash, which when included lowers gearing further. The current debt load looks manageable, with EBITDA interest cover of over 16 times and the nature of its businesses being relatively low risk. It is assumed AUB will use operating cash flows to fund increased positions in existing broker partners, with headroom to fund small acquisitions from cash on hand.

Bulls Say’s

  • AUB’s scale and expertise in insurance products and services leave it well placed to benefit from higher insurance pricing. 
  • BizCover and the Kelly+Partners partnership see AUB placed to take market share in the smaller end of the SME market. 
  • The firm’s acquisition strategy, both new investments and increased equity stakes, likely boosts EPS growth.

Company Profile 

AUB Group is the second-largest general insurance broker network in Australia and New Zealand. It has an ownership in 55 brokerage businesses, which collectively write over AUD 3 billion in premiums. It also owns equity stakes in 27 underwriting agencies. AUB derives revenue from commissions (from insurers, ultimately paid for by AUB’s customers) based on gross written premium, or GWP, from agencies it owns, and a share of profits from associates and joint ventures. GWP is split between personal (6%), small to medium enterprises (68%), and corporates (26%).

(Source: MorningStar)

General Advice Warning

Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.

Categories
Technology Stocks

REA Group reports strong FY21 earnings driven by growth in Australia segment

Investment Thesis:

  • Clear #1 market position in online property classifieds, with consumers spending over more time on realestate.com.au app than the number two website. 
  • Growth opportunities via expansion into Asia and North America. 
  • Recent strategic partnerships with National Australia Bank (property finance) could potentially be positive in the long term. 
  • Upside in key markets – particular in areas where REA is under-penetrated and could potentially win market share from competitors. 
  • New product developments to increase customer experience. 
  • Regular price increases help offset listing pressure.

Key Risks:

  • Competitive pressures lead to a further de-rating of the PE-multiple. 
  • Volume (listings) outlook remains subdued in the near term. 
  • Execution risk with Asia/North America strategy. 
  • Failing to get an adequate return on the recent acquisition of iProperty. 
  • Value/EPS destructive acquisitions. 
  • Decline in Australian property market. 
  • Given REA trades on a very high PE-multiple, underperforming to market estimates can exacerbate a share price de-rating. 
  • Recent tightening of lending practices by banks would affect Financial services business.

Key highlights:

  • REA reported strong FY21 results, with core operations revenue of $928m, up +13%, or excluding acquisitions, up +11%, on strong performance in its Australia segment.
  • EBITDA (incl. associates) was up +19% to $565m, on strong cost management with core operating cost growth (excluding acquisitions) contained to 3% over the pcp.
  • Margin of 60% was flat relative to the pcp. Net profit of $318m was up +18% equating to EPS of 247 cents, up +21%.
  • The Board declared a final dividend of 72cps fully franked which brings the full year dividend to 131cps, up +19%. 
  • Following several acquisitions, REA retained a strong balance sheet, with debt of $414m and a cash balance of $169m at year end.
  • REA refinanced syndicated debt facilities and funded the Mortgage Choice acquisition via a bridge facility with NAB for $520m. The bridge facility matures in July 2022, with management stating they expect to replace this with a new syndicated facility in 1Q22
  • Australia segment highlights:
    • Residential: revenue increased by +18%, on higher national listings (up +15% over the pcp, with Melbourne, up +11% and Sydney, up +25%), improved depth and Premiere penetration, increased subscription revenues and continued growth in add-on products.
    • Commercial and Developer: revenue was up +5% with Developer benefiting from a +17% increase in new project commencements, driven in part by Government stimulus, an increase in project profile duration and higher subscriptions, partially offset by lower Commercial revenues as the impact of Covid dampened listing volumes.
    • Media, Data & Other: revenues were broadly flat over the pcp, as growth in Data and Media revenues were offset by lower revenues in Other.
    • Financial Services: revenue was up +9% driven by higher settlements, increased broker recruitment and improved productivity, which was offset by lower partnership revenue as the current NAB agreement performance payments reached maturity in September 2020.

Company Description: 

REA Group (REA) provides online property listings, web management, financial services and data analytics to the real estate industry via advertising services. For consumers, REA offers the largest online real estate search engine in Australia. The Company also has operations and growing presence in Asia and other parts of the world.

(Source: Banyantree)

General Advice Warning

Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.

Categories
LICs LICs

Plato Income Maximiser Limited raises $139.5m

Plato Income is Financial Industry with sub- industry is Asset Management. Market Capitalization is 657.126m. Their 5 years Monthly Beta is 0.78. 

Plato Income’s NTA values shows below are before the dividend of $0.005 per share payable on 31 December 2021. The ex-date of the dividend is 16th December 2021. 

Plato Income Maximiser limited Pre – Tax NTA $1.101 while Post – tax NTA is 1.105. Per – tax NTA Includes tax on realised gains/losses and other earnings but excludes any provision from tax on unrealised gains/losses. Post – Tax NTA includes tax on realised and unrealised gains/losses and other earnings. 

During November, PL8 raised $139.5m in total through a Placement to wholesale investors and a Share Purchase Plan (SPP). The Placement to wholesale investors raised $71.3m with the issue of 64.3m fully paid ordinary shares at $1.11 per share. 

The SPP raised $68.2m through the issue of 62m new shares at $1.10 per share. The SPP was oversubscribed with the Company targeting $50m, however the Company decided not to scale back any applications.

The proceeds from the Placement and the SPP will be invested via the Plato Australian Shares Income Fund in accordance with the Company’s structure and investment strategy.

PL8 took the opportunity to raise capital when the Company was trading at a premium. The share price closed at $1.285 on 2 November, the day prior to the capital raising announcement, an 11.7% premium to the pre-tax NTA and a 15% premium to the post-tax NTA. 

The issue of new shares through the Placement and SPP has seen the share price decline to be trading closer to the pre-tax NTA at November-end.

Portfolio Performance as at 30th November 2021

PORTFOLIO PERFORMANCE¹1M%3M%1YR% P.A.3YRS% P.A.INCEPTION% P.A.
Total return²-0.7-2.114.813.59.6
Income³0.61.66.08.37.4
Bench. total return²-0.4-2.017.014.010.1
Excess total return²-0.3-0.1-2.2-0.5-0.5
Excess Income³0.0-0.11.13.42.2
Excess franking³0.00.00.51.20.9

Company Profile 

Plato Income Maximiser Limited is a listed investment company incorporated in Australia. The Company has been established to provide investors with the opportunity to benefit from an investment in an actively managed, well-diversified portfolio of Australian listed equities by investing in an the unlisted scheme Plato Australian Shares Income Fund.

(Source: BanyanTree)

General Advice Warning

Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.